Clinical trials: Sirolimus, completed
Leukemia, Lymphoma
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
RATIONALE: Giving total-body irradiation and chemotherapy, such as cyclophosphamide, before a donor stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells and helps stop the growth of…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00317785
- Testing
- cyclophosphamide, cyclosporine, methotrexate
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Coronary Artery Disease
The Dual Antiplatelet Therapy Study (DAPT Study)
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety…
- Trial name
- NCT00977938
- Testing
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Where
- 256 sites in United States, Australia and 8 more
- Volunteers
- 25,682 people
- Sponsor
- Baim Institute for Clinical Research
Advanced Cancer
Study of Rapamycin Plus Ketoconazole in Advanced Cancers
To determine the maximum tolerated dose, observed toxicities, and dose limiting toxicities, and antitumor response of rapamycin plus ketoconazole in patients with advanced cancers.
- Trial name
- NCT00708591
- Testing
- Rapamycin, Ketoconazole
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Chicago
Neuroendocrine Tumors
89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
This is a pilot study for evaluation of 89Zr-bevacizumab PET imaging as predictive biomarker during treatment with everolimus in patients with neuroendocrine tumors.
- Trial name
- NETPET (NCT01338090)
- Testing
- 89Zr-bevacizumab, Everolimus
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- University Medical Center Groningen
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
Palbociclib With Everolimus + Exemestane In BC
This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor positive (HR+) and…
- Trial name
- NCT02871791
- Testing
- Palbociclib, Everolimus, Exemestane
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Neoplasm
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
This phase I trial studies the side effects and best dose of cixutumumab and temsirolimus in treating patients with locally advanced or metastatic cancer.
- Trial name
- NCT00678769
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Cytomegalovirus Infection, Renal Transplant Failure
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
Despite the improvement of efficacy results with current immunosuppressive regimens (about 15% of incidence of acute rejection), the security schemes used do not show the same results.The most worldwide used regime is tacrolimus…
- Conditions
- Cytomegalovirus Infection, Renal Transplant Failure, Transplant; Complication, Rejection
- Trial name
- NCT01354301
- Testing
- Thymoglobulin, Everolimus, Basiliximabe
- Where
- Brazil
- Volunteers
- 300 people
- Sponsor
- Hospital do Rim e Hipertensão
Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
This phase II trial studies how well cixutumumab and temsirolimus work in treating patients with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma
- Trial name
- NCT01614795
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 76 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma, Non-Hodgkin
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
- Conditions
- Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
- Trial name
- NCT00350181
- Testing
- Sirolimus, MMF, BCNU
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Renal Cell Carcinoma
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
The purpose of this study is to test the safety and efficacy of the combination of erlotinib hydrochloride (Tarceva™) and sirolimus (Rapamune™) in the treatment of patients with metastatic kidney cancer.
- Trial name
- NCT00353301
- Testing
- Erlotinib hydrochloride, Sirolimus
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Colorado, Denver
Cognitive Impairment, Mild, Alzheimer Disease
Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and investigate associated safety, tolerability…
- Trial name
- CARPE_DIEM (NCT04200911)
- Testing
- Rapamune
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
In the treatment of castration-resistant prostate cancer (CRPC), therapies will long response durations remain elusive as a result of the inherent ability of prostate cancer cells to develop iterative resistance.
- Trial name
- NCT00630344
- Testing
- RAD001, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Kidney Transplantation
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
The purpose of the study in de novo renal transplant patients is to evaluate the effect on renal function of an optimized new regimen in comparison with the standard everolimus exposure plus a low-dose cyclosporine microemulsion…
- Trial name
- NCT00170885
- Testing
- Everolimus
- Where
- Switzerland
- Sponsor
- Novartis
Kidney Transplant
Planned Conversion From TAC to SRL-based Regimen in de Novo Kidney Transplant Recipients
Background Early conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitor is one of the immunosuppressive strategies that have been investigated to mitigate long-term CNi associated adverse events.
- Trial name
- NCT01802268
- Testing
- Conversion from Tacrolimus to Sirolimus, Maintenance on tacrolimus
- Where
- 6 sites in Brazil
- Volunteers
- 320 people
- Sponsor
- Helio Tedesco Silva Junior
Kidney Failure
Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
This study will test the safety and effectiveness of two drugs, Sirolimus and Thymoglobulin, for preventing rejection of transplanted kidneys.
- Trial name
- NCT00006178
- Testing
- Sirolimus, Thymoglobulin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Coronary Artery Disease
Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent
This is a prospective, multicenter, open-label, single-arm registry. The primary objective of this registry is to confirm the results of the Supraflex Cruz stent in real life all-comer patients (800 patients as in the Supraflex…
- Trial name
- NCT04138238
- Testing
- Supraflex Cruz Sirolimus-eluting Stent
- Where
- 26 sites in France, Germany and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Sahajanand Medical Technologies Limited
Coronary Artery Disease
First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis
Prospective, multi-center, randomized 1:1, single blind trial using BuMA Supreme versus Resolute Integrity conducted in approximately 14 interventional cardiology centers in The Netherlands, Belgium, Spain and Portugal.
- Trial name
- NCT02236975
- Testing
- BuMA Supreme Biodegradable drug coating coronary stent system, Resolute Integrity durable polymer stent system
- Where
- 12 sites in Belgium, Netherlands and 2 more
- Volunteers
- 168 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Non-Hodgkin's Lymphomas
The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas
This study is an open label, multicenter study with two phases: Phase I is a dose escalation study of RAD001 in combination with one injection of Rituximab 375 mg/m² per week during 4 weeks (28 days) in patients CD20 positive…
- Trial name
- (RAD001-R) (NCT01567475)
- Testing
- Everolimus and rituximab
- Where
- 5 sites in France
- Volunteers
- 21 people
- Sponsor
- The Lymphoma Academic Research Organisation
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
OPALINE : A Study Of Morbidity And Mortality At 2 Years
A descriptive, prospective (partly retrospective), multisite, observational study conducted in France in adult patients treated for a well differentiated, unresectable or metastatic, pancreatic neuroendocrine tumor with disease…
- Trial name
- OPALINE (NCT02264665)
- Testing
- sunitinib, everolimus, chemotherapies recommended in france
- Where
- 35 sites in France
- Volunteers
- 144 people
- Sponsor
- Pfizer
Thyroid Cancer
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise.
- Trial name
- NCT00936858
- Testing
- RAD001
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.